65,437 trials
Multiple Sclerosis · Spasticity · Pain
Primary: Incidence of Adverse Events as a Measure of Subject Safety. — 477 participants
Muscle Spasticity
Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients
Tinea Versicolor
Primary: The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor — 7; 4 participants
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Myopia
Primary: Front Surface Lens Deposits — 20; 25; 34; 29 Participants
Hepatitis C
Primary: Number of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Levels During Part 2 of the Study — 0; 2; 2; 2 participants
Flank Pain · Urinary Bladder, Overactive
Primary: Change in Post-ureteroscopy Stent-induced Pain — 4.61; 3.11 units on a scale
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (≥) 100 Milli-International Units Per Milliliter (mIU/mL) — 251 Participants
Actinic Keratosis
Primary: Incidence of AEs Recorded Throughout the Study — 12; 12; 8; 11 participants
Metastatic Renal Cell Carcinoma
Primary: Percentage of Participants With Objective Response — 25.3 percentage of participants
Opioid Analgesia
Primary: Single-dose PK Metric: Area Under the Plasma Concentration-time Curve From Hour 0 to the Last Measurable Plasma Concentration [AUCt] — 129.2; 121.1; 272.2; 85.5 ng*h/mL
Cystic Fibrosis
Primary: Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline) — 5.9; 6.7 Absolute % change
Diabetes
Primary: Recruitment, Retention, Adherence — 55 percentage of participants
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir · Critically Ill Requiring ECMO and Oseltamivir
Primary: Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance — 52.2; 43.3 mL/min
Obesity · Hypertension · Hyperglycemia
Primary: Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp — 5.3; 2.8 mg/kg/min